Global Leader In Biomanufacturing
Expanding To Meet Your Needs
-
Increased Capacity
US and European build out to support viral vector production -
Added Technology
iCellis platforms in process development (PD) and production increases options for adherent cell production -
Commercial Ready
Facilities in the US and Europe on track for commercial readiness in 2022
Expanding Global Capacity
Increase biomanufacturing and immunology capacities to support global clinical trials- Full complement of adherent cell production options (i.e. HYPERStacks®, cell factories and roller bottles)
- Experience manufacturing products for gene therapies, vaccines oncolytic vectors, proteins and critical reagents
- New iCELLis® GMP production suites
- New facility in Lyon, France increases GMP production by greater than 50%
Newly Added iCELLis® Technology
- A
BL’s recently added iCELLis® 500+ fixed-bed bioreactor provides a significant increase in volumetric productivity verses classical adherent methods - iCELLis® capability in process development laboratory and GMP suites creates predictable scalability from R&D to manufacturing
- New technology to meet your capacity requirements, streamline scalability and accelerate time to market
Global Commercial Ready
Commercial facilities in the U.S. and Europe (2021-22)- FDA and EMA compliant
- Viral vector and protein products produced for:
– Gene therapies
– Vaccines
– Oncolytics
– Immunotherapies
